Investing

Investment analysis, share recommendations, and market insights.

Premium

HOT stock: Pro Medicus (PME)

In our “HOT” stock column, Michael Gable, managing director of Fairmont Equities, explains why he’s still a buyer of PME for his clients.

Maureen Jordan · August 1, 2024
Premium

Is Macquarie a buy over $200?

I’m a great believer in backing track record, so there’s no argument from me when it comes to Macquarie. It is, and remains, a core portfolio stock. The question however is where it sits in the current market: is this a point to acquire more, ease back a touch and take a profit on a small portion, or just sit back?

Paul Rickard · July 29, 2024
Premium

4 cancer fighting stocks

The ASX has a burgeoning life sciences cohort doing great work in a range of major diseases. Here are four interesting cancer fighters.

James Dunn · July 29, 2024
Premium

“HOT” stock: Audinate (ASX:AD8)

In our “HOT” stock column, Michael Wayne, Managing Director of Medallion Financial Group, says that for investors who feared they may have missed their chance with Audinate, the current price may present an attractive opportunity to begin accumulating a high-quality growth business during a pull-back.

Maureen Jordan · July 25, 2024
Premium

Should we dump HNDQ and tech stocks?

HNDQ and going long the Nasdaq’s top stocks has been a rewarding play but is it time to take profit and look for another play that will be helped by the rotation out of big tech into smaller growth stocks? As one investing door closes, another one opens, so let’s go looking for a good door for the year ahead.

Peter Switzer · July 22, 2024

You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.